HAIKOU, China, Aug. 6, 2018 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listedcorporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its second quarter 2018 earnings conference call on Wednesday, August
Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 6869537. A replay of the call will be accessible through August 23, 2018 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 6869537.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.
China Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/cphi-to-hold-second-quarter-2018-earnings-conference-call-on-wednesday-august-15-2018-at-830-am-et-300692284.html
SOURCE China Pharma Holdings, Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All